Advertisement
Home Tags Prescription Drugs

Tag: Prescription Drugs

The drug eteplirsen should not be approved for treatment of Duchenne muscular dystrophy

FDA Panel Votes Against Approval of Eteplirsen for DMD

0
Clinical data did not meet the agency's requirements for well controlled studies necessary for approval
The addition of tiotropium to long-acting β2-agonists (LABA) and/or inhaled corticosteroids (ICS) does not reduce chronic obstructive pulmonary disease exacerbations compared to LABA/ICS alone

Triple Therapy No Benefit for COPD Exacerbations

0
Findings based long-acting β2-agonists, inhaled corticosteroids + tiotropium
Use of saxagliptin or sitagliptin is not associated with increased risk of hospitalized heart failure compared with other antihyperglycemic agents

Saxagliptin, Sitagliptin Don’t Up Hospitalized Heart Failure

0
No increased risk for new users of saxagliptin, sitagliptin versus other antihyperglycemic agents
A considerable proportion of patients with actinic keratosis receiving long-term topical treatment have poor persistence or adherence

Poor Persistence/Adherence With Long-Term Topical AK Treatment

0
Many patients non-persistent or over-persistent; 75 percent adherent to recalled frequency, regularity
In a case report published online April 11 in the Journal of Diabetes Investigation

Rapid-Onset Diabetes Described With Anti-PD-1 Treatment

0
Case report of rapid-onset insulin-dependent diabetes with anti-programmed cell death 1 therapy
Varenicline (Chantix) and bupropion (Wellbutrin) don't appear to raise the risk of mental health disorders such as depression

No Link for Smoking Cessation Meds, Mental Health Issues

0
Meds like varenicline and bupropion may be safer to use than smokers often realize
For patients with psoriasis

Ustekinumab More Effective Than TNF-α Inhibitors in Psoriasis

0
Ustekinumab more effective than three tumor necrosis factor-α-inhibitors at six, 12 months
Treatment with aromatase inhibitors doesn't raise the risk of the most fatal cardiovascular disease events among breast cancer survivors

Aromatase Inhibitors Won’t Raise Odds of Most Fatal CVD Events

0
But there is a slightly increased risk of less serious cardiovascular issues
Pembrolizumab is associated with an overall objective response rate of 33 percent in patients with advanced melanoma

Pembrolizumab Active in Patients With Advanced Melanoma

0
Overall response rate of 33 percent for total population, 45 percent among treatment naive

American Association for Cancer Research, April 16-20

0
The American Association for Cancer Research Annual Meeting The annual meeting of the American Association for Cancer Research was held from April 16...